PolyPid Announces Planned CEO Transition

Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022 PETAH TIKVA, Israel , Jan. 03, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and